FOXO4
Senolytic Peptide
- Form
- Lyophilized powder
- Storage
- -20°C (lyophilized)
- Origin
- USA lab
$689
FOXO4 is a synthetic peptide reference material used in laboratory investigations of the FOXO4-p53 interaction and senolytic-signaling research.
- FOXO4-p53 interaction research
- Senolytic-signaling models
- In-vitro cellular-senescence studies
SKU: AP-FOXO4-10MG
3 vial minimum per order — mix any products
Research Use Only
All products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.
Reconstitution ReferenceOptional — how strong is the mixed vial?
Mixing a powder vial with water? Fill in the fields — results update as you type.
Mixing 10 mg of peptide into 2 mL of water makes a 5 mg/mL solution. Each 0.1 mL contains 0.5 mg.
Reference for in-vitro laboratory handling only. Outputs describe the physical properties of the reconstituted vial (concentration and mass drawn) — they are not dosing guidance, administration instructions, or medical advice. Verify all measurements independently.
The science behind FOXO4
A structured overview of the published literature surrounding the FOXO4-DRI peptide as a senescence-research compound.
FOXO4 (studied as the FOXO4-DRI peptide) is a synthetic D-retro-inverso peptide designed to interfere with the interaction between the FOXO4 transcription factor and the tumor-suppressor protein p53. It is used as a reference tool in cellular-senescence research.
The compound gained attention through preclinical senolytic research, where it is studied for its reported ability to influence senescent-cell viability in experimental models.
The material supplied here is a laboratory reference standard, and the summaries below describe only findings reported in published research.
FOXO4-DRI was engineered from research into the FOXO4–p53 axis in senescent cells. The D-retro-inverso design was chosen to improve stability against proteolysis in experimental systems.
The literature is early-stage and predominantly in-vitro and rodent-based, originating largely from foundational senolytics research. Human clinical evidence has not been established.
The mechanism of interest is disruption of the FOXO4–p53 interaction. In senescent-cell models this is reported to influence p53 localization and downstream apoptotic signaling.
This selective effect on senescent cells is the basis for classifying the compound within the "senolytic" research category — findings that remain exploratory laboratory observations.
Cellular-senescence models
Used to probe senescent-cell viability in vitro.
FOXO4–p53 interaction
Examined in protein-interaction and localization studies.
Senolytic research
Referenced in the emerging literature on selective senescent-cell clearance.
Aging-biology systems
Explored in preclinical models of tissue aging.
What is the FOXO4 peptide?
A synthetic D-retro-inverso peptide (FOXO4-DRI) that interferes with the FOXO4–p53 interaction, supplied as a laboratory reference material for senescence research.
What kind of research references FOXO4-DRI?
Early-stage in-vitro and rodent senolytics studies. Human clinical evidence has not been established.
Is The FOXO4 peptide approved for human or veterinary use?
No. The FOXO4 peptide is not approved by the FDA or any regulatory authority for human or animal use. It is sold exclusively for in-vitro and laboratory research and is not for consumption.
How is the reference material characterized?
Each released lot is supplied as a lyophilized powder with a lot-specific certificate of analysis reporting HPLC purity of ≥ 99%. The certificate is tied to the specific released lot.
How should the compound be stored?
Lyophilized material is typically stored at -20°C, protected from light and moisture. Handling should follow standard laboratory practice for peptide reference materials. We do not provide reconstitution, dosing, or administration guidance.
- Baar MP, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell (2017).
- Senolytics and the FOXO4–p53 axis (review).
Links open a curated peer-reviewed search on PubMed. Allpointe Bio Research is not affiliated with the cited authors or publishers.
Research-Use Statement
The information above is provided for educational and scientific-reference purposes only and summarizes findings reported in the published preclinical and in-vitro literature. It is not medical advice and does not describe outcomes, benefits, or applications for humans or animals. FOXO4 is supplied strictly as a laboratory reference material for in-vitro and research use only — it is not a drug or supplement, is not approved for human or veterinary use, and is not for consumption. Allpointe Bio Research does not provide clinical, dosing, reconstitution, or administration guidance.